busulfan

(redirected from Busulfex)
Also found in: Dictionary, Medical.

busulfan

[‚byü′səl·fən]
(pharmacology)
CH3SO2O(CH2)4OSO2CH3 Crystals with a melting point of 114-118°C; soluble in acetone at 25°C; used as an antineoplastic drug.
References in periodicals archive ?
The company stated that the Myleran (busulfan) Injection, 60 mg/10 ml (6 mg/ml) single-dose vial is the generic version of Otsuka Pharmaceutical's Busulfex Injection.
IV Busulfex is used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.
Additionally, the new formulations of intravenous busulfan, such as Busulfex (dissolved in dimethylacetamide) and a liposomal form, require clinical trials that include an evaluation of pharmacokinetic parameters, especially in children.
Orphan Medical also announced it has signed a letter of intent with Pierre Fabre Medicament, Paris, France, that would grant the company exclusive rights to market and distribute Busulfex in Europe, Argentina and South Africa.
A privately owned company Tzamal Pharma LTD has been given the right to distribute Busulfex in Israel.
Learn how Pierre Fabres oncology franchise, driven by Javlor and Busulfex, will propel the companys overall growth performance
Minneapolis, MN, announced the US Food and Drug Administration (FDA) Oncology Drugs Advisory Committee has recommended unanimously that Busulfex (busflfan) injection be approved to prepare certain patients for bone marrow and blood stem cell transplants.
Frestedt served as Manager of Clinical Affairs for Ortho Biotech, a Johnson and Johnson company; Operations Manager for Mayo Clinical Trial Services at the Mayo Clinic in Rochester, Minnesota; Medical Information Scientist for Astra Zeneca Pharmaceuticals; and Manager of Busulfex Clinical Development for Orphan Medical in Minnetonka, Minnesota.
With our existing product portfolio and 2003 acquisitions, including IV Busulfex, gross 2003 revenues are expected to exceed $60 million, nearly a fourfold increase from $16 million achieved during eight months of operations ended Dec.
Busulfex is used as a conditioning regimen prior to hematopoietic progenitor cell transplantation.
Busulfex, which is used in preparative regimens for bone marrow transplantation, increased its market share to 55 percent in transplants where busulfan-based regimens are used.